Trends in Drug Spending of Oral Anticoagulants for Atrial Fibrillation, 2014-2021.

ABSTRACT:

Introduction

This study documents cost trends in oral anticoagulants (OAC) in patients with newly diagnosed atrial fibrillation.

Methods

Using MarketScan databases, the mean annual patients' out-of-pocket costs, insurance payments, and the proportion of patients initiating OAC within 90 days from atrial fibrillation diagnosis were calculated from July 2014 to June 2021. Costs of OACs (apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin) and the payments by three insurance types (commercial payers, Medicare, and Medicaid) were calculated. Patients' out-of-pocket costs and insurance payments were adjusted to 2021 prices. Joinpoint regression models were used to test trends of outcomes and average annual percent changes (AAPC) were reported. Data analyses were performed i

SUBMITTER: Lee JS 

PROVIDER: S-EPMC10922581 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature